{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'microscopy. Follow up of abnormal results will be guided by the algorithm below in Appendix B', '(Anti-Glomerular Basement Membrane Disease).', '9.3.4 Hemophagocytic lymphohistiocytosis', 'During postmarketing use, HLH has been reported in patients treated with alemtuzumab.', 'Hemophagocytic lymphohistiocytosis is a life-threatening syndrome of pathologic immune', 'activation characterized by clinical signs and symptoms of extreme systemic inflammation,', 'including fever, swollen lymph nodes, bruising or skin rash. It is associated with high mortality', 'rates if not recognized early and treated. Symptoms have been reported to occur within a few', 'months to four years following the initiation of treatment. Patients who develop disease', 'manifestations of pathologic immune activation should be evaluated immediately, and a diagnosis', 'of HLH as well as referral of the patient to a specialist should be considered.', '9.3.5 Physical examination and vital signs', 'Whenever possible, the same physician should perform the physical examination at all study', 'visits. The findings of each examination will be recorded.', 'A standard physical examination for clinical and neurological assessments which includes', 'examination of major body systems, height and body weight will be performed.', 'Physical examination and vital signs will be performed at screening, D-14 to D-7, M0/D1, M4,', 'M8, M12, M15, M18, M21, M24/at EOTP; every 6 months safety monitoring phase, and at every', 'relapse visit.', 'The following vital signs: respiratory rate, heart rate, systolic and diastolic blood pressure and', 'body temperature, will be measured during each physical examination and at the following', 'timepoints during alemtuzumab treatment:', 'Before methylprednisolone infusion.', 'At a time after methylprednisolone infusion and prior to alemtuzumab infusion.', '1 hour after the start of alemtuzumab infusion and hourly during and after infusion, until', '2 hours after infusion has ended or longer until stabilization.', 'Body temperature will be collected using the same method at each assessment for a given patient.', 'Blood pressure will be measured under standardized conditions using the same method at each', 'assessment for a given patient. It will be determined at each study visit using a well calibrated', 'apparatus. Both systolic and diastolic blood pressure must be recorded.', 'The date of the first menarche should be captured if applicable.', 'The Tanner stage (Appendix E) should be assessed until complete sexual maturity at the specified', 'time points, see Study flowchart Section 1.2 for further details.', 'Property of the Sanofi Group - strictly confidential', 'Page 61', 'VV-CLIN-02544065 5.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'The Tanner scale (also known as the Tanner stages I-V) is a scale of physical development in', 'children, adolescents and adults (23, 24). The scale defines physical measurements of', 'development based on external primary and secondary sex characteristics, such as the size of the', 'breasts, genitalia, and development of pubic hair. Tanner scale is performed either at the study site', 'by the paediatric neurologist or paediatrician or at a designated site arranged by the Investigator.', '9.3.6 Other safety endpoints', 'The other safety endpoints will be assessed by:', 'Antidrug antibody formation (ADA).', 'Assessment of ADA formation will be performed at M0/D1 (baseline), post dose, M1, M3, M12', '(prenext dose), M13, M15, M24/at EOTP, and annually in the safety monitoring phase.', 'IV infusion of alemtuzumab has been associated with the development of antialemtuzumab', 'antibodies and inhibitory antibodies. Serum samples will be tested by established assay methods', 'for the presence of antialemtuzumab antibodies and titers will be quantified for positive samples.', '9.4', 'EXPLORATORY ENDPOINT', 'T1 weighted lesions and brain volume will be assessed on MRI as an exploratory endpoint MRI', 'throughout the study period.', '9.5', 'FUTURE USE OF SAMPLES', '9.5.1 Immune markers (optional)', 'Based on the increased risk of autoimmune events observed with alemtuzumab, serum will be', 'collected to support investigation of potential biomarkers predictive of the response to', 'alemtuzumab. The markers to be tested may include cytokines and possibly other serum', 'components; the specific markers to be assessed will be guided by results of ongoing biomarker', 'investigations with alemtuzumab.', 'If the patient accepts to sign the specific informed consent form (ICF), \"Future Use of Samples\",', 'serum samples and peripheral blood mononuclear cell will be collected at the visit specified in the', 'study flow chart (designated \"immune markers\") and these samples will be stored to support', 'future investigation of potential biomarkers predictive of autoimmunity, such as serum cytokines.', '9.6', 'APPROPRIATENESS OF MEASUREMENTS', 'The primary endpoint is the number of new or enlarging T2 lesions during continuation of prior', 'DMT (Period 1) and during an approximately equal period of time after Course 1 of alemtuzumab', 'treatment (Period 2) This endpoint was agreed upon by the Paediatric Committee (PDCO to', 'protect the study population from any significant treatment-free period and provide an analysis of', 'Property of the Sanofi Group - strictly confidential', 'Page 62', 'VV-CLIN-02544065.0']\n\n###\n\n", "completion": "END"}